- Analysis of 11,163 IVF Patients with Exactly One Fertilized Egg: Per-patient live birth rate stood at 12.5% for the cleavage-stage (Day 2–3) transfer strategy vs. 10.1% for the blastocyst (Day 5) strategy
- Per-Transfer Rates Favor Blastocysts, But the Real Risk is Ending with ‘Zero Transferable Embryos’: Extended culture eliminates transfer opportunities for a substantial subset of patients
- Advantage of Cleavage-Stage Transfer Increases with Age: Relative live birth probability for the cleavage strategy was 34% higher at age 35 and 51% higher at age 40
“I only have one fertilized egg. Should we still push it to Day 5?”
For patients undergoing In Vitro Fertilization (IVF), this is a critical dilemma. When multiple embryos are available, extended culture to Day 5 or 6 allows embryologists to select the most developmentally competent blastocyst. However, when only a single normally fertilized egg (2PN zygote) is obtained, the equation shifts entirely: if that single embryo arrests in culture, the entire cycle is canceled with zero opportunity for embryo transfer.
A study published in the July 2026 issue of the international journal Human Reproduction investigated this exact question.
Researchers from the University of New South Wales, Monash IVF, and collaborating institutions analyzed 11,163 women across Australia and New Zealand who underwent their first IVF or ICSI cycle between 2009 and 2022 and produced exactly one normally fertilized oocyte.
The research question was straightforward: For a single fertilized egg, is it better to transfer at the cleavage stage (Day 2–3) or pursue extended culture to the blastocyst stage (Day 5)?
Per-Patient Strategy: Cleavage Stage Yields Higher Live Birth Rates
The findings challenged the widespread clinical assumption that “Day 5 blastocysts are always superior.”
When evaluating outcomes on an intention-to-treat (per-patient) strategy basis:
- Live Birth Rate (LBR) per Patient: 12.5% for the cleavage-stage transfer strategy vs. 10.1% for the blastocyst strategy (an absolute difference of 2.4 percentage points, representing a 24% higher relative risk favoring cleavage transfer).
- Clinical Pregnancy Rate: 17.0% for cleavage-stage vs. 13.4% for blastocyst culture.
The disparity widened significantly with advancing maternal age:
- At age 35: The estimated live birth probability was 34% higher with the cleavage-stage strategy.
- At age 40: The cleavage strategy yielded a 51% higher relative probability of live birth.
While the statistical model indicated that approximately 92% of fertilized eggs survived to the cleavage stage regardless of age, the probability of reaching the blastocyst stage declined sharply with age—dropping to 58.9% at age 35 and 49.9% at age 40.
Survivor Bias: Per-Transfer vs. Per-Patient Success
To accurately interpret these findings, a clear distinction must be made between per-transfer success and per-patient success.
When looking exclusively at cycles where an embryo transfer actually took place:
- Per-Transfer Live Birth Rate: 18.4% for blastocysts vs. 13.5% for cleavage-stage embryos.
Embryos that successfully survive to become blastocysts retain higher individual implantation potential. However, pursuing that blastocyst comes at a high cost: many patients experience culture arrest and end up with no embryo to transfer.
This disparity illustrates survivor bias. When clinics report that “Day 5 embryos yield higher success rates,” the figure is often calculated only among embryos that survived to transfer. For patients, the relevant metric is their cumulative chance of taking home a baby calculated from the moment a single fertilized egg is confirmed. Evaluating only surviving blastocysts excludes arrested embryos and canceled cycles from the denominator.
Similar trends have been observed in earlier literature:
- A 2022 study evaluating patients with ≤4 fertilized eggs found that 35.2% of cycles in the Day-5 extended culture group were canceled with zero blastocysts available for transfer or cryopreservation, compared to only 10.3% cancellation in the Day-3 transfer group (though final cumulative live birth rates across all cycles remained comparable).
Nuance: The Role of Embryo Selection
These findings should not lead to the oversimplified conclusion that “cleavage-stage transfer is universally superior for all patients.”
Cochrane systematic reviews confirm that for patients with a favorable prognosis and multiple embryos, Day-5 blastocyst transfer achieves higher live birth rates in fresh IVF cycles. However, that evidence base is derived primarily from good-prognosis cohorts with multiple embryos to select from. Applying the same strategy to low-prognosis patients with only one or two zygotes represents an entirely different clinical scenario.
Furthermore, it cannot be assumed that an embryo that arrested in the laboratory by Day 5 would have resulted in a viable pregnancy if transferred on Day 3. An embryo lacking intrinsic developmental competence would likely fail to implant or progress in utero as well.
The takeaway of this study is not that “the uterus is unconditionally superior to the incubator,” but rather that when only one embryo exists, the potential benefit of extended culture for embryo selection is outweighed by the risk of cycle cancellation.
Study Design and Limitations
The study utilized a target trial emulation design based on retrospective registry data from the Australian and New Zealand Assisted Reproduction Database (ANZARD).
Limitations to consider include:
- The registry data did not explicitly record whether a Day-3 or Day-5 transfer was planned at baseline, requiring researchers to estimate treatment allocation using statistical modeling.
- Granular clinical variables—such as day-of-transfer morphological grading and baseline body mass index (BMI)—were unavailable in the dataset.
- As a non-randomized observational design, the findings provide strong epidemiological evidence but do not yet constitute a randomized controlled trial establishing a new universal standard of care.
Conclusion
The primary clinical advantage of blastocyst culture is selection—identifying the most competent embryo among a cohort of several. When a patient has only one embryo, the opportunity for selection is absent. At that point, extended culture ceases to be a selection tool and becomes an attrition test for the patient’s sole opportunity for transfer.
This analysis of 11,163 patients does not invalidate the biological viability of blastocysts. Rather, it reframes the rigid dogma that extended culture must be universally applied to every patient regardless of embryo yield.
In IVF, the number of available embryos dictates clinical strategy just as much as embryo quality. For a patient with a single fertilized egg, the fundamental clinical question becomes:
“Is our priority to prolong laboratory selection, or is it to safeguard the patient’s opportunity to undergo an embryo transfer?”
※ This article was synthesized based on the study by Fitzgerald et al. published in Human Reproduction (July 2026), Cochrane systematic reviews, and relevant reproductive medicine literature. It does not replace individualized clinical diagnosis or medical care, and specific treatment decisions should be made in consultation with a qualified specialist physician.
※ The images associated with this article were generated using generative AI (ChatGPT, OpenAI) as illustrative references and do not depict real individuals.